MEK inhibitors for the treatment of non | 合法藥品大搜索

A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2. They can be used to affect the ... Read More

由 J Han 著作 · 2021 · 被引用 5 次 — To date, four MEK inhibitors have been approved by the United States Food and Drug Administration (FDA), including trametinib, binimetinib, ... Read More

由 Y Cheng 著作 · 2017 · 被引用 88 次 — Trametinib became the first approved drug among MEK inhibitors, and cobimetinib soon followed suit. MEK inhibitors as single agents or in ... Read More

由 J Han 著作 · 2021 · 被引用 5 次 — To date, four MEK inhibitors have been approved by the United States Food and Drug Administration (FDA), including trametinib, binimetinib, ... Read More

由 AM Grimaldi 著作 · 2017 · 被引用 73 次 — These mutations have become targets for new therapeutic strategies in melanoma and other cancers. Selective MEK inhibitors have the ability to inhibit growth ... Read More

由 JJ Luke 著作 · 2014 · 被引用 32 次 — The biology of MEK inhibition is complex, as the molecule is differentially regulated by upstream RAS or RAF. This has impacted on the past development of MEK ... Read More

MEK inhibitors (e.g., refametinib, selumetinib, trametinib, cobimetinib) have been tested in clinical trials for the treatment of NSCLC. ... The most common ... Read More

2019年8月21日 — MEK1 and MEK2 inhibitors are highly selective anti-cancer drugs targeting the MAPK pathway. Selective MEK inhibitors can relieve symptoms and ... Read More